glp 1 agonist and pregnancy Discontinuing GLP-1s before or early during raises risk for complications GLP-1 Receptor Agonist Use Across
Description
The underlying pathophysiological mechanism of IIH has yet to be established

The therapeutic potential of GLP-1 is limited by its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4)

3.1.2 Anti-inflammatory and immunomodulatory effects Chronic hepatic inflammation, driven by activated Kupffer cells, infiltrating macrophages, and pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF- ) and interleukin-6 (IL-6), is a crucial factor in MASLD progression to steatohepatitis and fibrosis

2,3 Obesity is a complex, multifactorial condition influenced by various interrelated factors, including lifestyle, medications, genetics, medical conditions, gut hormones and psychological aspects
It has been documented to enhance GLP-1 secretion, primarily aiding in the maintenance of healthy blood glucose levels
71 Furthermore, GLP-1RA has been investigated for its potential to reduce the risk of cardiovascular events in patients with or without diabetes
